Therapeutic antibody blockade of CSF1R and IL-8 signaling may disrupt CTC interactions with myeloid cells, impairing CTC proliferation and motility, while allowing for GM-CSF-driven APC to re-activate tumor responsive T lymphocytes that had been anergized by immunosuppressive environment of PDAC portal blood. The gene discussed is CSF2; the disease is neoplasm.